Stemline Therapeutics Inc (STML) COO Sells $195,577.20 in Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 14,040 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $13.93, for a total value of $195,577.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kenneth Hoberman also recently made the following trade(s):

  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,351.74.
  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,918.94.

Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded up $0.25 on Friday, hitting $14.10. The stock had a trading volume of 100,595 shares, compared to its average volume of 208,878. Stemline Therapeutics Inc has a 12-month low of $5.50 and a 12-month high of $16.20. The company has a market capitalization of $352.75, a PE ratio of -5.49 and a beta of -0.02.

Several institutional investors and hedge funds have recently made changes to their positions in STML. Rhumbline Advisers increased its position in shares of Stemline Therapeutics by 18.5% during the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 4,280 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Stemline Therapeutics during the second quarter valued at about $147,000. AXA increased its position in shares of Stemline Therapeutics by 44.9% during the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock valued at $5,789,000 after buying an additional 195,022 shares during the period. Alliancebernstein L.P. bought a new stake in shares of Stemline Therapeutics during the second quarter valued at about $178,000. Finally, Teachers Advisors LLC increased its position in shares of Stemline Therapeutics by 1.3% during the second quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 541 shares during the period. Hedge funds and other institutional investors own 50.24% of the company’s stock.

A number of brokerages recently issued reports on STML. BidaskClub cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 14th. Finally, Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $33.75.

WARNING: “Stemline Therapeutics Inc (STML) COO Sells $195,577.20 in Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/12/stemline-therapeutics-inc-stml-coo-sells-195577-20-in-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit